{"id":6931,"date":"2023-10-05T10:15:00","date_gmt":"2023-10-05T10:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/"},"modified":"2023-11-13T18:54:48","modified_gmt":"2023-11-13T17:54:48","slug":"nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/","title":{"rendered":"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB meddelar idag att fas I-studien NEX-20-01 har slutf\u00f6rts med de sista uppf\u00f6ljningsbes\u00f6ken f\u00f6r den sista av de tre dosniv\u00e5erna som studerats. Nanexa har tidigare kommunicerat positiva resultat fr\u00e5n den farmakokinetiska utv\u00e4rderingen och har nu \u00e4ven avslutat insamling av s\u00e4kerhets- och tolerabilitetsdata som ocks\u00e5 st\u00f6djer projektets vidare utveckling.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>NEX-20-01 p\u00e5visade inte n\u00e5gra ov\u00e4ntade fynd som ifr\u00e5gas\u00e4tter s\u00e4kerheten av lenalidomid som dep\u00e5beredning med PharmaShell\u00ae. D\u00e4remot s\u00e5gs lokala reaktioner med rodnad och\/eller svullnad motsvarande injektionsomr\u00e5det med den givna formuleringen av NEX-20. Reaktionerna varierade fr\u00e5n milda vid de l\u00e4gre dosniv\u00e5erna till moderata vid h\u00f6gre dos. Samtliga reaktioner klingade av under studietiden.<\/p>\n<p>N\u00e4sta steg i det kliniska programmet f\u00f6r NEX-20 \u00e4r att forts\u00e4tta med doseskalering till terapeutiska niv\u00e5er i patienter. Den formulering som studerades i NEX-20-01 visar en farmakokinetisk profil med kontrollerad fris\u00e4ttning som \u00e4r n\u00e4ra det som kr\u00e4vs f\u00f6r dosering en g\u00e5ng i m\u00e5naden.<\/p>\n<p>Parallellt med den genomf\u00f6rda kliniska studien har en preklinisk studie gjorts i minigris med en ny formulering av NEX-20 med signifikant mindre svullnad vid injektionsst\u00e4llet j\u00e4mf\u00f6rt med den formulering som anv\u00e4nts i NEX-20-01. Denna formulering ska vidareutvecklas och testas ytterligare prekliniskt f\u00f6r att minimera lokala reaktioner i n\u00e4sta kliniska studie.<\/p>\n<p>\u201dVi bryter ny mark med NEX-20\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa. \u201dDet h\u00e4r \u00e4r f\u00f6rsta g\u00e5ngen lenalidomid administrerats som en subkutan injektion i m\u00e4nniska, oss veterligen. Vi \u00e4r glada att vi har en PharmaShell formulering av NEX-20 som ger en kontrollerad fris\u00e4ttning och att vi med PharmaShell-systemet har goda f\u00f6ruts\u00e4ttningar att minimera v\u00e4vnadsp\u00e5verkan vid injektionsst\u00e4llet vilket \u00e4r en k\u00e4nd utmaning f\u00f6r subkutant administrerade dep\u00e5l\u00e4kemedel.\u201d<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/f3754fea-a22f-42fd-a4eb-f55721b0eb8f\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB meddelar idag att fas I-studien NEX-20-01 har slutf\u00f6rts med de sista uppf\u00f6ljningsbes\u00f6ken f\u00f6r den sista av de tre dosniv\u00e5erna som studerats. Nanexa har tidigare kommunicerat positiva resultat fr\u00e5n den farmakokinetiska utv\u00e4rderingen och har nu \u00e4ven avslutat insamling av s\u00e4kerhets- och tolerabilitetsdata som ocks\u00e5 st\u00f6djer projektets vidare utveckling.<\/p>\n","protected":false},"template":"","class_list":["post-6931","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att fas I-studien NEX-20-01 har slutf\u00f6rts med de sista uppf\u00f6ljningsbes\u00f6ken f\u00f6r den sista av de tre dosniv\u00e5erna som studerats. Nanexa har tidigare kommunicerat positiva resultat fr\u00e5n den farmakokinetiska utv\u00e4rderingen och har nu \u00e4ven avslutat insamling av s\u00e4kerhets- och tolerabilitetsdata som ocks\u00e5 st\u00f6djer projektets vidare utveckling.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-13T17:54:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\\\/\",\"name\":\"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-10-05T10:15:00+00:00\",\"dateModified\":\"2023-11-13T17:54:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB","og_description":"Nanexa AB meddelar idag att fas I-studien NEX-20-01 har slutf\u00f6rts med de sista uppf\u00f6ljningsbes\u00f6ken f\u00f6r den sista av de tre dosniv\u00e5erna som studerats. Nanexa har tidigare kommunicerat positiva resultat fr\u00e5n den farmakokinetiska utv\u00e4rderingen och har nu \u00e4ven avslutat insamling av s\u00e4kerhets- och tolerabilitetsdata som ocks\u00e5 st\u00f6djer projektets vidare utveckling.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/","og_site_name":"Nanexa AB","article_modified_time":"2023-11-13T17:54:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/","name":"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-10-05T10:15:00+00:00","dateModified":"2023-11-13T17:54:48+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-kliniska-fas-i-studien-med-nex-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa har slutf\u00f6rt den kliniska fas I-studien med NEX-20"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}